Last reviewed · How we verify
PF-07038124 (pf-07038124)
PF-07038124 is a topical PDE4 inhibitor that blocks phosphodiesterase-4 to reduce inflammatory cytokine production in skin immune cells.
PF-07038124, a topical PDE4 inhibitor by Pfizer, currently holds no approved indications and competes in a crowded market with established drugs like Crisaborole and Dupilumab. Its mechanism of action as a PDE4 inhibitor offers a targeted approach to reducing inflammation in skin conditions, aligning it with the first-in-class Crisaborole but lacking current regulatory approval. A key risk is the presence of multiple approved competitors, including JAK inhibitors from Pfizer itself and other major players, which may limit its market penetration. Despite this, the ongoing clinical trials and potential for new indications, particularly those requiring a PD-L1 companion diagnostic, suggest a promising pipeline that could enhance its future market position.
At a glance
| Generic name | pf-07038124 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Phosphodiesterase-4 inhibitor |
| Target | Phosphodiesterase-4 (PDE4) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | discontinued |
Mechanism of action
PF-07038124 works by inhibiting phosphodiesterase-4 (PDE4), an enzyme found in immune cells that normally breaks down cyclic adenosine monophosphate (cAMP). By blocking PDE4, the drug increases intracellular cAMP levels, which suppresses the production of pro-inflammatory cytokines such as TNF-α, IL-2, and IL-6. This mechanism reduces the activation and proliferation of T cells and other immune cells that drive inflammatory skin diseases. As a topical formulation, PF-07038124 delivers the drug directly to affected skin tissue, minimizing systemic exposure and potential off-target effects associated with oral PDE4 inhibitors. The selective inhibition of PDE4 in dermal immune cells creates a localized anti-inflammatory effect without broad immunosuppression.
Approved indications
Pipeline indications
- Atopic Dermatitis — Phase 2
- Plaque Psoriasis — Phase 2
- Vitiligo — Phase 2
- Seborrheic Dermatitis — Phase 2
- Papulopustular Rosacea — Phase 2
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07038124 CI brief — competitive landscape report
- PF-07038124 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI